Basit öğe kaydını göster

dc.contributor.authorAnak, Sema
dc.contributor.authorYalman, Nevin
dc.contributor.authorBilgen, Hülya
dc.contributor.authorSepet, Elif
dc.contributor.authorDeviren, Ayhan
dc.contributor.authorGürtekin, Başak
dc.contributor.authorTunca, Fatih
dc.contributor.authorBaşaran, Bora
dc.date.accessioned2020-07-29T09:28:18Z
dc.date.available2020-07-29T09:28:18Z
dc.date.issued2020en_US
dc.identifier.citationAnak, S., Yalman, N., Bilgen, H., Sepet, E., Deviren, A., Gürtekin, B. ... Başaran, B. (2020). Squamous cell carcinoma development in Fanconi anemia patients who underwent hematopoietic stem cell transplantation. Pediatric Transplantation, 24(4). https://dx.doi.org/10.1111/petr.13706en_US
dc.identifier.issn1397-3142
dc.identifier.issn1399-3046
dc.identifier.urihttps://dx.doi.org/10.1111/petr.13706
dc.identifier.urihttps://hdl.handle.net/20.500.12511/5640
dc.description.abstractWe examined SCC development of 24 FA patients, who received HSCT from HLA-matched relatives. In our BMT center, we applied low-dose CY + LFI + ATG (n:13) as conditioning regimen for FA patients between 1992 and 1999, and CY + BU + ATG (n:11) between 1999 and 2002. The aim of this study was to investigate SCC development after HSCT and examine features of the follow-up patients. The 10-year overall survival (OS) of the group with LFI + regimen was 43%, whereas the group without LFI regimen was 60%. There was a statistically significant relationship between infections (viral/bacterial) and overall survival (Fisher's Exact test P < .001). Five out of 13 long-term (>1 year) surviving patients developed SCC in the HNSCC (n:4) and esophagus (n:2) region (a patient with oral SCC developed a second primary esophageal SCC). The SCC rate in our FA patients was 38%, four of the SCC patients were transplanted with irradiation used conditioning regimens, three of them had acuteGvHD (Grade II-III), only one developed chronic GvHD. The interval between HSCT and SCC diagnosis was median 13 (range 6-18) years, the age for the development of cancer was median 21 (range 15-32) years. Survival after SCC was low, median 6 months (range 6-12), due to delayed SCC diagnosis, tumor progression under therapy and treatment-related toxicities of the usually reduced RT and/or CT.en_US
dc.language.isoengen_US
dc.publisherWileyen_US
dc.rightsinfo:eu-repo/semantics/embargoedAccessen_US
dc.subjectFanconi Anemiaen_US
dc.subjectGvHDen_US
dc.subjectHematopoietic Stem Cell Transplantationen_US
dc.subjectSquamous Cell Carcinomaen_US
dc.titleSquamous cell carcinoma development in Fanconi anemia patients who underwent hematopoietic stem cell transplantationen_US
dc.typearticleen_US
dc.relation.ispartofPediatric Transplantationen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalıen_US
dc.authorid0000-0001-8489-7449en_US
dc.authorid0000-0002-7424-8688en_US
dc.identifier.volume24en_US
dc.identifier.issue4en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.1111/petr.13706en_US
dc.identifier.wosqualityQ4en_US
dc.identifier.scopusqualityQ2en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster